Irbesartan + Hidroclorotiazida Ratiopharm

Irbesartan, the active ingredient in Irbesartan + Hidroclorotiazida Ratiopharm, is an angiotensin II receptor blocker presented as a tablet for oral use. It is combined with hydrochlorothiazide, a thiazide diuretic, and together they are used to treat hypertension in adult patients.

GNH USA supplies Irbesartan + Hidroclorotiazida Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with full regulatory compliance, quality assurance, and reliable logistics.

Irbesartan/Hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system and fluid balance to lower elevated blood pressure. - Essential hypertension: reduces systolic and diastolic blood pressure to target levels. - Hypertension with fluid retention: promotes diuresis and decreases plasma volume. - Hypertension in type 2 diabetes: helps control blood pressure and may provide renal protective benefits.

Common Side Effects: - Dizziness or light‑headedness. - Headache. - Fatigue or weakness. - Increased urination. - Electrolyte disturbances such as low potassium. - Mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hypotension. - Acute kidney injury or worsening renal function. - Hyperkalemia. - Allergic reactions including rash or angioedema. - Pancreatitis. - Blood cell abnormalities such as leukopenia.

Before initiating therapy, consider the following precautions: - Monitor blood pressure: check regularly to ensure therapeutic response. - Assess renal function: obtain baseline creatinine and eGFR, repeat as needed. - Check electrolytes: especially potassium and sodium levels. - Avoid use in pregnancy: classified as Category D due to fetal risk. - Use caution in elderly patients: increased susceptibility to volume depletion. - Store at ambient temperature: keep in the original container, protect from moisture.

Irbesartan/Hydrochlorothiazide may interact with several medicines. Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - ACE inhibitors or ARBs combined with aliskiren in diabetic patients: increased renal risk. - Lithium: may raise lithium concentrations and toxicity. - NSAIDs: can blunt antihypertensive effect and affect renal function. Moderate Interactions (Monitor Closely): - Other antihypertensives: additive blood pressure lowering. - Corticosteroids: may increase sodium retention. - Beta‑blockers: may mask tachycardia from hypotension.